Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print      Mail a friend

Thursday 02 July, 2020

Oxford Biomedica PLC

Director Dealings / Market Share Purchase

RNS Number : 9022R
Oxford Biomedica PLC
02 July 2020
 

 

 

 

Director Dealings / Market Share Purchase

 

Oxford, UK - 02 July 2020:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund, a person closely associated with Martin Diggle, Non-Executive Director, has purchased 8,181 ordinary shares of 50p each ("Ordinary Shares") in the Company on 01 July 2020 on the London Stock Exchange at a price of 719.6p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 11,460,616 ordinary shares representing 14.0% of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 

 1.

Details of the person discharging material responsibilities/person closely   associated

 

 a.

Name

Vulpes Testudo Fund

 

 2.

Reason for the notification

 

 a.

Position/status

Person closely associated with Martin Diggle, Non-Executive Director

 

 b.

Initial notification /amendment

 Initial notification

 

3.

Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor

 

 a.

Name

 Oxford Biomedica plc

 

 b.

Legal Entity Identifier

 213800S1GVQNXQ15K851

 

4.

Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 a.

Description of the financial instrument, type of instrument identification code

 Oxford Biomedica plc Ordinary Shares of 50p each

 

 

 GB00BDFBVT43

 

b.

Nature of the transaction

 Purchase of ordinary shares

 

 

c.

Currency

 GBP - British Pound

 

d.

Price(s) and volume(s)

 

Price(s)

 

 

Volume(s)

£7.20

 

8,181

 

 

 

 

e.

Aggregated information

· Aggregated volume

· Price

· Aggregated total

 

 

8,181

 

£7.1956

£58,867.20

 

f.

Date of the transaction

 2020-07-01

 

g.

Place of the transaction

 London Stock Exchange, Main Market (XLON)

 

 

 

The issued share capital of the Group is 82,046,996 ordinary 50p shares.

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at  www.oxb.com .

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHUUOSRRBUBRAR

a d v e r t i s e m e n t